These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 15733831)

  • 1. Tumor necrosis factor, cancer and anticancer therapy.
    Mocellin S; Rossi CR; Pilati P; Nitti D
    Cytokine Growth Factor Rev; 2005 Feb; 16(1):35-53. PubMed ID: 15733831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The dual role of tumor necrosis factor (TNF) in cancer biology.
    Bertazza L; Mocellin S
    Curr Med Chem; 2010; 17(29):3337-3352. PubMed ID: 20712570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor necrosis factor-alpha therapy and potential cancer inhibition.
    Williams GM
    Eur J Cancer Prev; 2008 Apr; 17(2):169-77. PubMed ID: 18287875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Tumor necrosis factor: pleiotropic cytokine].
    Chouaib S; Robinet E; Zyad A; Branellec D
    Bull Cancer; 1992; 79(10):935-49. PubMed ID: 1292760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review. TNF/VEGF cross-talk in chronic inflammation-related cancer initiation and progression: an early target in anticancer therapeutic strategy.
    Guadagni F; Ferroni P; Palmirotta R; Portarena I; Formica V; Roselli M
    In Vivo; 2007; 21(2):147-61. PubMed ID: 17436563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies for improving the anti-neoplastic activity of TNF by tumor targeting.
    Corti A
    Methods Mol Med; 2004; 98():247-64. PubMed ID: 15064445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour necrosis factor: strategies for improving the therapeutic index.
    Corti A; Marcucci F
    J Drug Target; 1998; 5(6):403-13. PubMed ID: 9783674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving TNF as a cancer therapeutic: tailor-made TNF fusion proteins with conserved antitumor activity and reduced systemic side effects.
    Gerspach J; Pfizenmaier K; Wajant H
    Biofactors; 2009; 35(4):364-72. PubMed ID: 19484741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience of EET therapy for 75 advanced cancer patients.
    Kato M; Shinohara H; Goto S; Takagi K; Soma G
    Anticancer Res; 1998; 18(5D):3941-9. PubMed ID: 9854508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor therapeutics by design: targeting and activation of death receptors.
    Wajant H; Gerspach J; Pfizenmaier K
    Cytokine Growth Factor Rev; 2005 Feb; 16(1):55-76. PubMed ID: 15733832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cloning, expression, purification of rat tumor necrosis factor and demonstration of its antitumor activity in Bomirski amelanotic melanoma.
    Koszałka P; Breza H; Bigda J
    Neoplasma; 1998; 45(3):162-8. PubMed ID: 9717529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer.
    Anderson GM; Nakada MT; DeWitte M
    Curr Opin Pharmacol; 2004 Aug; 4(4):314-20. PubMed ID: 15251122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour necrosis factor and cancer treatment: a historical review and perspectives.
    Terlikowski SJ
    Rocz Akad Med Bialymst; 2001; 46():5-18. PubMed ID: 11780579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changing the pathophysiology of solid tumours: the potential of TNF and other vasoactive agents.
    ten Hagen TL; Eggermont AM
    Int J Hyperthermia; 2006 May; 22(3):241-6. PubMed ID: 16754345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience and long-term follow-up.
    McLoughlin JM; McCarty TM; Cunningham C; Clark V; Senzer N; Nemunaitis J; Kuhn JA
    Ann Surg Oncol; 2005 Oct; 12(10):825-30. PubMed ID: 16132372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A mutated human tumor necrosis factor-alpha improves the therapeutic index in vitro and in vivo.
    Yan Z; Zhao N; Wang Z; Li B; Bao C; Shi J; Han W; Zhang Y
    Cytotherapy; 2006; 8(4):415-23. PubMed ID: 16923618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regional application of TNF alpha in the treatment of cancer: a preclinical-clinical interactive program.
    Eggermont AM; Manusama ER; ten Hagen TL
    J Inflamm; 1995-1996; 47(1-2):104-13. PubMed ID: 8913937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of endothelial monocyte activating polypeptide II in tumor necrosis factor-alpha-based anti-cancer therapy.
    Lans TE; Van Horssen R; Eggermont AM; Ten Hagen TL
    Anticancer Res; 2004; 24(4):2243-8. PubMed ID: 15330168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation.
    Imre G; Gekeler V; Leja A; Beckers T; Boehm M
    Cancer Res; 2006 May; 66(10):5409-18. PubMed ID: 16707469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.